Syndax prepays $21.5M loan, terminates Hercules Capital credit agreement

Syndax Pharmaceuticals Inc

Prepaid $21.5M to Hercules Capital to satisfy all principal, interest, and fees under Feb 2020 loan; includes $1.0M end-of-term fee and $0.4M prepayment fee.
Hercules released all security interests on Syndax assets; loan agreement fully terminated as of September 23, 2022.
Prepayment does not alter prior guidance: current cash sufficient to fund operations into second half of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.